Halozyme Therapeutics, Inc. (HALO) vs Madrigal Pharmaceuticals, Inc. (MDGL)

Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $13.1B against $11.9B — 1.1× the size. Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 32.4×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 41.2%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs −25.3%) and the higher return on invested capital (18.1% vs −787.3%). Across the 18 metrics below, Halozyme Therapeutics, Inc. leads on 11 and Madrigal Pharmaceuticals, Inc. on 7.